Histone Deacetylase (HDAC) inhibitors, often known as HDIs, are a class of drugs that promote lysine acetylation on histone proteins and other non-histone proteins by reducing HDAC enzyme activity. They are employed as mood stabilisers and anti-epileptics in psychiatry and neurology. HDAC are anticancer medications because they cause cancer cell cycle arrest, differentiation, and cell death, as well as reducing angiogenesis and modulating immune response.
The primary driving reasons for the histone deacetylase HDAC Inhibitors Market include an increase in cancer occurrences, a significant unmet need in the treatment landscape, and a demand for histone deacetylase inhibitors. The reimbursement, uncertainty, and stringent reimbursement regulations may hinder market growth.
Read More @ https://cmiinfopiece.blogspot.com/2022/06/increasing-r-for-cancer-is-expected-to.html
